zepbound tirzepatide patent expiration Doors open for a wave of cheap weight-loss drugs Zepbound: The newest obesity medication

Hudspeth, PharmD, an associate professor and the chief practice officer at the University of Kentucky College of Pharmacy in Lexington

To read the full 2026 Healthcare Equality Index report, please click here.

If you switch vials mid-protocol, especially between different pharmacies or different lots, be aware that your effective dose may shift slightly even if your unit measurements remain constant

Thierry AR, Salmon D

However, KYNA influences AMPAR activity predominantly through indirect mechanisms, namely its non-competitive allosteric inhibition of presynaptic 7nAChRs on glutamatergic terminals in mood-related circuits, leading to reduced glutamate release and downstream modulation of excitatory signalling [29, 30]

Switching GLP-1 medications should be done with your prescribing physician